GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Assertio Holdings Inc (FRA:DPOA) » Definitions » Short Percentage of Float

Assertio Holdings (FRA:DPOA) Short Percentage of Float


View and export this data going back to 2018. Start your Free Trial

What is Assertio Holdings Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Assertio Holdings's Short Percentage of Float

For the Drug Manufacturers - Specialty & Generic subindustry, Assertio Holdings's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Assertio Holdings's Short Percentage of Float Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Assertio Holdings's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Assertio Holdings's Short Percentage of Float falls into.


Assertio Holdings (FRA:DPOA) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Assertio Holdings Inc (FRA:DPOA) » Definitions » Short Percentage of Float
Comparable Companies
ETON MRMD SCYX BKUH TKNO DERM SSIC ETST RGC OPTN XTER:MRK ZTS NSE:SUNPHARMA TSE:4502 LSE:HLN XTAE:TEVA XSWX:SDZ NBIX SZSE:000538 NSE:DIVISLAB
Traded in Other Exchanges
ASRT:USA
Address
100 South Saunders Road, Suite 300, Lake Forest, IL, USA, 60045
Website
https://www.assertiotx.com
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults 18 years of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain.

Assertio Holdings (FRA:DPOA) Headlines

No Headlines